1. Safety Alert: Immune Globulin Intravenous (Human) [IGIV]. FDA Medwatch safety alerts for human medical products Web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154633.htm. Accessed 19 Sep 2011
2. Dear Manufacturer: Immune Globulin Intravenous (Human) (IGIV); Required updates to product labeling. FDA center for biologics evaluation and research letters to industry/Healthcare Providers/Clinical Investigators Web site. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm093491.htm. Accessed 19 Sep 2011
3. FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm375096.htm. Accessed 19 Nov 2013
4. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R (2005) Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 16(5):313–318
5. Winiecki S. Adverse Event Reports to FDA for Immunoglobulins and TEEs. Paper presented at: U.S. Food and Drug Administration Public Workshop: Risk Mitigation Strategies to Address Procoagulant Activity in Immune Globulin Products; May 17, 2011; Shady Grove conference Center, Rockville, MD